{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:28:24Z","timestamp":1776713304378,"version":"3.51.2"},"reference-count":131,"publisher":"Elsevier BV","issue":"21-22","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.drudis.2012.06.017","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T07:15:51Z","timestamp":1341472551000},"page":"1217-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting mutant huntingtin for the development of disease-modifying therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Thomas","family":"Appl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Kaltenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg C.","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2012.06.017_bib0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington's disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2012.06.017_bib0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0015","series-title":"Neurobiology of Huntington's Disease: Applications to Drug Discovery","first-page":"197","article-title":"Pharmaceutical development for Huntington's disease","author":"Morse","year":"2011"},{"key":"10.1016\/j.drudis.2012.06.017_bib0020","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2012.06.017_bib0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/hmg\/7.5.783","article-title":"Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture","volume":"7","author":"Cooper","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0035","article-title":"Protein aggregates in Huntington's disease","author":"Arrasate","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.drudis.2009.02.006","article-title":"Small molecule drug discovery for Huntington's disease","volume":"14","author":"Fecke","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2012.06.017_bib0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.drudis.2012.06.017_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/hmg\/ddq148","article-title":"Huntington's disease: progress toward effective disease-modifying treatments and a cure","volume":"19","author":"Johnson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.drudis.2012.06.017_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","article-title":"A systematic review of the treatment studies in Huntington's disease since 1990","volume":"8","author":"Bonelli","year":"2007","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2012.06.017_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2012.06.017_bib0075","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1586\/ern.10.105","article-title":"Cholinesterase inhibitors: beyond Alzheimer's disease","volume":"10","author":"Larner","year":"2010","journal-title":"Exp. Rev. Neurother."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2012.06.017_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1752-0509-1-S1-P45","article-title":"Huntington's disease: from experimental models to interaction networks, patho-pathway construction and disease hypothesis","volume":"1","author":"Gonzalez-Couto","year":"2007","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0085","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1371\/journal.pgen.0030082","article-title":"Huntingtin interacting proteins are genetic modifiers of neurodegeneration","volume":"3","author":"Kaltenbach","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","article-title":"Identifying druggable disease-modifying gene products","volume":"13","author":"Dixon","year":"2009","journal-title":"Curr. Opin Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0095","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2012.06.017_bib0100","series-title":"Neurobiology of Huntington's Disease: Applications to Drug Discovery","article-title":"Target validation for Huntington's disease","author":"Kwak","year":"2011"},{"key":"10.1016\/j.drudis.2012.06.017_bib0105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuron.2005.11.008","article-title":"Silencing polyglutamine degeneration with RNAi","volume":"48","author":"Bonini","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2012.06.017_bib0110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0120","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0130","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2012.06.017_bib0135","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2012.06.017_bib0140","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0145","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0150","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archneurol.2009.180","article-title":"Progress and challenges in RNA interference therapy for Huntington disease","volume":"66","author":"Harper","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0155","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00439-011-0995-8","article-title":"RNAi: a potential new class of therapeutic for human genetic disease","volume":"130","author":"Seyhan","year":"2011","journal-title":"Hum. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2012.06.017_bib0165","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/ijms10062510","article-title":"Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders","volume":"10","author":"Choonara","year":"2009","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1089\/hum.2010.083","article-title":"High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain","volume":"22","author":"Uno","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0175","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","article-title":"RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia","volume":"10","author":"Xia","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0180","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","article-title":"Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice","volume":"24","author":"Zu","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm1205","article-title":"Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model","volume":"11","author":"Ralph","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/hum.2010.054","article-title":"In vivo application of an RNAi strategy for the selective suppression of a mutant allele","volume":"22","author":"Kubodera","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0195","doi-asserted-by":"crossref","first-page":"e21352","DOI":"10.1371\/journal.pone.0021352","article-title":"Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi","volume":"6","author":"de Ynigo-Mojado","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0200","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2012.06.017_bib0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.201003-0422OC","article-title":"RNA interference therapy in lung transplant patients infected with respiratory syncytial virus","volume":"183","author":"Zamora","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0215","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2012.06.017_bib0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/jid.2010.372","article-title":"Development of quantitative molecular clinical end points for siRNA clinical trials","volume":"131","author":"Hickerson","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0230","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2012.06.017_bib0235","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/mt.2011.232","article-title":"Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy","volume":"20","author":"Osman","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0245","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0250","doi-asserted-by":"crossref","first-page":"8404","DOI":"10.1021\/ja200312y","article-title":"Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide\u2013oligospermine conjugates","volume":"133","author":"Gagnon","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2012.06.017_bib0255","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0260","doi-asserted-by":"crossref","first-page":"e16676","DOI":"10.1371\/journal.pone.0016676","article-title":"Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1","volume":"6","author":"Southwell","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0265","doi-asserted-by":"crossref","first-page":"17616","DOI":"10.1073\/pnas.0408134101","article-title":"Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody","volume":"101","author":"Colby","year":"2004","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2012.06.017_bib0270","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0275","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0280","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14712590903176387","article-title":"Developing intrabodies for the therapeutic suppression of neurodegenerative pathology","volume":"9","author":"Messer","year":"2009","journal-title":"Exp. Opin. Biol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0285","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14712598.2011.552884","article-title":"Antibody-based therapy in Alzheimer's disease","volume":"11","author":"Pul","year":"2011","journal-title":"Exp. Opin. Biol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0290","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/mds.23902","article-title":"Can we reverse alpha-synuclein lesions?","volume":"26","author":"Przedborski","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.drudis.2012.06.017_bib0295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/hmg\/ddn412","article-title":"Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity","volume":"18","author":"Pennuto","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0300","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2007.09.009","article-title":"Kinase packing defects as drug targets","volume":"12","author":"Crespo","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2012.06.017_bib0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12264-010-1118-6","article-title":"The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease","volume":"26","author":"Wang","year":"2010","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.drudis.2012.06.017_bib0310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.drudis.2012.06.017_bib0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.pneurobio.2011.11.002","article-title":"Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases","volume":"97","author":"Young","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1092194","article-title":"SUMO modification of Huntingtin and Huntington's disease pathology","volume":"304","author":"Steffan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.drudis.2012.06.017_bib0325","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2012.06.017_bib0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10555-006-7890-0","article-title":"Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer","volume":"25","author":"Overall","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.drudis.2012.06.017_bib0335","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases","volume":"6","author":"Hu","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2012.06.017_bib0340","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12035-008-8036-x","article-title":"Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration","volume":"38","author":"Vosler","year":"2008","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0345","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","article-title":"Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease","volume":"67","author":"Miller","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2012.06.017_bib0350","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.jcbfm.9600595","article-title":"Mechanistic role of calpains in postischemic neurodegeneration","volume":"28","author":"Bevers","year":"2008","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.drudis.2012.06.017_bib0355","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10571-007-9220-7","article-title":"Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range","volume":"27","author":"Majumder","year":"2007","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0360","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1523\/JNEUROSCI.4619-08.2008","article-title":"Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity","volume":"28","author":"Cowan","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0365","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1523\/JNEUROSCI.22-12-04842.2002","article-title":"Calpain activation in Huntington's disease","volume":"22","author":"Gafni","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0370","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0375","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0380","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1074\/jbc.M401267200","article-title":"Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain\/caspase fragments in the nucleus","volume":"279","author":"Gafni","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0385","doi-asserted-by":"crossref","first-page":"19831","DOI":"10.1074\/jbc.M001475200","article-title":"Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells","volume":"275","author":"Wellington","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0390","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0395","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjp.0705662","article-title":"Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease","volume":"141","author":"Toulmond","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0400","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbrc.2010.12.106","article-title":"ARP101, a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells","volume":"404","author":"Jo","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2012.06.017_bib0405","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pharmthera.2011.07.003","article-title":"Allosteric modulation of caspases","volume":"132","author":"Hacker","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0410","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/13543776.2011.568480","article-title":"Calpain inhibitors: a survey of compounds reported in the patent and scientific literature","volume":"21","author":"Donkor","year":"2011","journal-title":"Exp. Opin. Ther. Pat."},{"key":"10.1016\/j.drudis.2012.06.017_bib0415","first-page":"343","article-title":"Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation","volume":"45","author":"Mikosik","year":"2007","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0420","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1016\/j.bmc.2011.08.020","article-title":"Exploiting differences in caspase-2 and -3 S subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors","volume":"19","author":"Maillard","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0425","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/jm0210717","article-title":"Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability","volume":"46","author":"Lubisch","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0430","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2174\/138161206775474314","article-title":"Calpain inhibition: a therapeutic strategy targeting multiple disease states","volume":"12","author":"Carragher","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2012.06.017_bib0435","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.chembiol.2010.08.014","article-title":"Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models","volume":"17","author":"Leyva","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0440","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1755-5949.2010.00184.x","article-title":"Targeting histone deacetylases for the treatment of Huntington's disease","volume":"16","author":"Gray","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.drudis.2012.06.017_bib0445","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","article-title":"Histone deacetylase inhibitors as therapeutics for polyglutamine disorders","volume":"7","author":"Butler","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0450","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2012.06.017_bib0455","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12035-009-8067-y","article-title":"Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors","volume":"40","author":"Thomas","year":"2009","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0460","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","article-title":"Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Bobrowska","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0465","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","article-title":"Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington's disease","volume":"4","author":"Benn","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0470","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","article-title":"Genetic knock-down of Hdac3 does not modify disease-related phenotypes in a mouse model of Huntington's disease","volume":"7","author":"Moumne","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0475","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2012.06.017_bib0480","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1074\/mcp.M111.009829","article-title":"Mass spectrometric identification of novel lysine acetylation sites in huntingtin","volume":"10","author":"Cong","year":"2011","journal-title":"Mol. Cell Proteom."},{"key":"10.1016\/j.drudis.2012.06.017_bib0490","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0495","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng1534","article-title":"Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons","volume":"37","author":"Parker","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0500","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","article-title":"Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway","volume":"18","author":"Jeong","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0505","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","article-title":"Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets","volume":"18","author":"Jiang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2012.06.017_bib0510","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2012.06.017_bib0515","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrm3293","article-title":"Sirtuins as regulators of metabolism and healthspan","volume":"13","author":"Houtkooper","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0520","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","article-title":"Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity","volume":"284","author":"Aiken","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0525","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","article-title":"Kinase inhibitors modulate huntingtin cell localization and toxicity","volume":"7","author":"Atwal","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0530","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/hmg\/ddr023","article-title":"Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation","volume":"20","author":"Havel","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0535","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200909067","article-title":"IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome","volume":"187","author":"Thompson","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0540","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2012.06.017_bib0545","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0550","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/hmg\/ddi165","article-title":"Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo","volume":"14","author":"Warby","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2012.06.017_bib0555","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.1523\/JNEUROSCI.1589-10.2010","article-title":"Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A","volume":"30","author":"Metzler","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0560","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/emboj.2008.133","article-title":"Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons","volume":"27","author":"Colin","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2012.06.017_bib0565","doi-asserted-by":"crossref","first-page":"23686","DOI":"10.1074\/jbc.M513507200","article-title":"Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity","volume":"281","author":"Schilling","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0570","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1523\/JNEUROSCI.1831-07.2007","article-title":"Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons","volume":"27","author":"Anne","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0575","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1083\/jcb.200412071","article-title":"Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity","volume":"169","author":"Luo","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0580","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2009.02.015","article-title":"From promiscuity to precision: protein phosphatases get a makeover","volume":"33","author":"Virshup","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drudis.2012.06.017_bib0585","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cbpa.2009.03.021","article-title":"The therapeutic potential of phosphatase inhibitors","volume":"13","author":"Vintonyak","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0590","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4155\/fmc.11.47","article-title":"Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease","volume":"3","author":"Voronkov","year":"2011","journal-title":"Fut. Med. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0595","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.bmc.2011.02.047","article-title":"Using small molecules to target protein phosphatases","volume":"19","author":"Vintonyak","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0600","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.biochem.73.011303.074118","article-title":"Protein modification by SUMO","volume":"73","author":"Johnson","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0605","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0610","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.1172871","article-title":"Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity","volume":"324","author":"Subramaniam","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drudis.2012.06.017_bib0615","doi-asserted-by":"crossref","first-page":"20428","DOI":"10.1074\/jbc.C110.127191","article-title":"Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9","volume":"285","author":"Subramaniam","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0620","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.1645","article-title":"Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase","volume":"28","author":"Aghajan","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0625","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.chembiol.2011.05.008","article-title":"Development of small molecule inhibitors and probes of human SUMO deconjugating proteases","volume":"18","author":"Albrow","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0630","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.biochem.73.011303.073954","article-title":"Palmitoylation of intracellular signaling proteins: regulation and function","volume":"73","author":"Smotrys","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.drudis.2012.06.017_bib0635","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nn1702","article-title":"Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function","volume":"9","author":"Yanai","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.drudis.2012.06.017_bib0640","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nchembio.362","article-title":"Small-molecule inhibition of APT1 affects Ras localization and signaling","volume":"6","author":"Dekker","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drudis.2012.06.017_bib0645","unstructured":"Ramaswamy, S. and Kordower, J.H. Gene therapy for Huntington's disease. Neurobiol. Dis. (in press)"},{"key":"10.1016\/j.drudis.2012.06.017_bib0650","series-title":"Neurobiology of Huntington's Disease: Applications to Drug Discovery","article-title":"RNA- and DNA-based therapies for Huntington's disease","author":"Meghan","year":"2011"},{"key":"10.1016\/j.drudis.2012.06.017_bib0655","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog. Neurobiol."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644612002334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644612002334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:12:57Z","timestamp":1761221577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644612002334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":131,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1359644612002334"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2012.06.017","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting mutant huntingtin for the development of disease-modifying therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2012.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}